Last checked at 26 Sep 2018 17:12
26 September 2018
Frontier IP Group plc
("Frontier IP" or the "Group")
Director Declaration
Frontier IP, which specialises in commercialising university intellectual property, makes the following updated disclosures in respect of Neil Crabb, CEO of Frontier IP, pursuant to Schedule 2(g) of the AIM Rules for Companies:
a) Mr Crabb was appointed as a director of B1 Medical Limited on 14 July 2006 and was a director when the company entered into compulsory liquidation on 1 November 2012. B1 Medical Limited was dissolved on 5 February 2013.
b) Mr Crabb was appointed as a director of Intelligent Flow Solutions Limited on 27 March 2012 and was a director when the company entered into compulsory liquidation on 26 October 2016.
There are no further disclosures required pursuant to Schedule 2(g).
Enquiries:
| Frontier IP Group plc | T: 0131 240 1251 |
| Neil Crabb, Chief Executive |
|
| Andrew Johnson, Communications & Investor Relations | M: 07464 546 025 |
| www.frontierip.co.uk |
|
|
|
|
| Cenkos Securities plc (Nominated Adviser and Joint Broker) | T: 0131 220 6939 |
| Neil McDonald / Beth McKiernan |
|
|
|
|
| Peterhouse Corporate Finance Limited (Joint Broker) | T: 020 7469 0935 |
| Lucy Williams |
|
|
|
|
| Kreab (Financial PR) | T: 0207 074 1800 |
| Robert Speed / Matthew Jervois |
|
Notes to Editors:
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.